Combination of immunotherapy and traditional chemotherapy, such as triple therapy for lung cancer that includes carboplatin, pembrolizumab (a programmed cell death-1 [PD-1] inhibitor), and pemetrexed, poses important diagnostic challenges, as all 3 of these drugs may lead to AKI. The gene discussed is PDCD1; the disease is lung cancer.